2024
Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity
Chetty A, Khunte M, Chen A, Jastreboff A, Krumholz H, Lu Y. Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity. American Heart Journal 2024, 278: 8. DOI: 10.1016/j.ahj.2024.09.022.Peer-Reviewed Original ResearchTirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff A, le Roux C, Stefanski A, Aronne L, Halpern B, Wharton S, Wilding J, Perreault L, Zhang S, Battula R, Bunck M, Ahmad N, Jouravskaya I. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal Of Medicine 2024 PMID: 39536238, DOI: 10.1056/nejmoa2410819.Peer-Reviewed Original ResearchType 2 diabetesProgression to type 2 diabetesDose escalation periodRisk of progression to type 2 diabetesBody weightDoses of tirzepatideBaseline to weekOnce-weekly dosingOff-treatment periodSustained weight reductionYear of treatmentDiagnosis of type 2 diabetesAssigned doseDouble-blindPlacebo groupAdverse eventsTirzepatideTirzepatide groupsPlaceboCausal precursorsSafety signalsObesity treatmentSustained reductionDelay progression to type 2 diabetesObesitySurvodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024 PMID: 39495965, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesityEligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity
Chetty A, Khunte M, Chen A, Jastreboff A, Krumholz H, Lu Y. Eligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity. Journal Of General Internal Medicine 2024, 1-3. PMID: 39477867, DOI: 10.1007/s11606-024-09178-8.Peer-Reviewed Original ResearchGLP-1 programs the neurovascular landscape
Chen B, Yu X, Horvath-Diano C, Ortuño M, Tschöp M, Jastreboff A, Schneeberger M. GLP-1 programs the neurovascular landscape. Cell Metabolism 2024, 36: 2173-2189. PMID: 39357509, DOI: 10.1016/j.cmet.2024.09.003.Peer-Reviewed Original ResearchConceptsGLP-1R agonismGLP-1RMetabolic healthChronic low-grade inflammationLow-grade inflammationGlucagon-like peptide-1 receptorPersistent health issuesCognitive well-beingNutrient-rich foodsPeptide-1 receptorMetabolic syndromeHealth issuesMetabolic defectsBrain healthMetabolic environmentObesityWell-beingWeight lossHealthMetabolic conditionsAgonismNeurological conditionsConsiderations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
Kelly A, Bahlke M, Baker J, de Beaufort C, Belin R, Fonseca H, Hale P, Holm J, Hsia D, Jastreboff A, Juliusson P, Murphy M, Pak J, Paul E, Rudolph B, Srivastava G, Tornøe C, Weghuber D, Fox C. Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings. Pediatric Obesity 2024, 19: e13161. PMID: 39289849, DOI: 10.1111/ijpo.13161.Peer-Reviewed Original ResearchAnti-obesity medicationsExcessive weight reductionClinical trialsEnd pointsDown-titrationEligibility criteriaLong-term health outcomesBMI z-scoreActive comparatorEfficacy end pointPlacebo-controlled trialSecondary end pointsRun-in phaseFollow-up periodFollow-up phaseHealth outcomesObesity expertsTrial eligibility criteriaClinical careWeight reductionMultidisciplinary groupClinical trial protocolsPrimary outcomeWeight regainTrial protocolSemaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Deanfield J, Verma S, Scirica B, Kahn S, Emerson S, Ryan D, Lingvay I, Colhoun H, Plutzky J, Kosiborod M, Hovingh G, Hardt-Lindberg S, Frenkel O, Weeke P, Rasmussen S, Goudev A, Lang C, Urina-Triana M, Pietilä M, Lincoff A, Investigators S, Abe M, Abhaichand R, Abhayaratna W, Abhyankar A, Abidin I, Assi H, Mendoza J, Adas M, Agaiby J, Agarwal D, Agha M, Ahmed A, Ahtiainen P, Aigner E, Ajay N, Ali N, Al-Karadsheh A, Allison R, Allison D, Alpenidze D, Altuntas Y, Al-Zoebi A, Ambuj R, Amerena J, Anderson R, Ando T, Andrews R, Antonova E, Appel K, Arantes F, Araz M, Arbel Y, León J, Argyrakopoulou G, Ariani M, Mendoza M, Arif A, Arneja J, Aroda V, Aronne L, Arstall M, Asamoah N, Asanin M, Audish H, Avram R, Badat A, Badiu C, Bakdash W, Bakiner O, Bandezi V, Bang L, Bansal S, Baranyai M, Barbarash O, Barber M, Barnum O, Rochette G, Bashkin A, Baum S, Bays H, Ruiz A, Beckowski M, Beerachee Y, Bellary S, Belousova L, Berk M, Bernstein M, Berra C, Beshay I, Bhagwat A, Bhan A, Biggs W, Billings L, Bitar F, Block B, Bo S, Bogdanski P, Bolshakova O, Boshchenko A, Bosworth H, Lopez R, Bôttcher M, Bourgeois R, Brautigam D, Breton C, Broadley A, Brockmyre A, Brodie S, Bucci M, Budincevic H, Budoff M, Buffman B, Buljubasic N, Buranapin S, Burgess L, Burguera B, Buriakovska O, Buscemi S, Busch R, Buse J, Buynak R, Byrne M, Caceaune E, Bonfanti A, Calinescu C, Call R, Varzic S, Cannon K, Capehorn M, Cariou B, Carr J, Carrillo-Jimenez R, Casas M, Castro A, Celik A, Cercato C, Cermak O, Y J, Chacon C, Chaicha-Brom T, Chandra S, Chettibi M, Chevts J, Christopher J, Chrustowski W, Cif A, Clark R, Clark W, Clifford P, Coetzee K, Cogni G, Colao A, Colquhoun D, Concha M, Condit J, Constance C, Constantin C, Constantinescu S, Corbett C, Cornett G, Correia M, Cortinovis F, Cosma D, Creely S, Cross D, Curtis B, Czochra W, Daboul N, Dagdelen S, D'agostino R, Dang C, Datta S, Davuluri A, Dawood S, De Jong D, De La Cuesta C, De Los Rios Ibarra M, De Pablo C, De Pauw M, Dela Llana A, Delibasic M, Delic-Brkljacic D, Demicheli T, Denger R, Desai D, Desai P, Desouza C, Dicker D, Djenic N, Dobson S, Doi M, Doran J, Dorman R, Dotta F, Dukes C, Duronto E, Durst R, Dvoryashina I, Ebrahim I, Eggebrecht H, Egstrup K, Ekinci E, Eliasson B, Eliasson K, Enache G, Enculescu D, English P, Ermakova P, Ershova O, Ezaki H, Ezhov M, Farias E, Farias J, Farsky P, Ferreira D, Filteau P, Finneran M, Folkens E, Fonseca A, Fonseca L, Fordan S, Fourie N, França S, Franco D, Franek E, Friedman K, Frittitta L, Froer M, Fuckar K, Fujii K, Fujita R, Fukushima Y, Fulat M, Fulwani M, Gajos G, Galyavich A, Gambill M, Gandotra D, Winston G, Hernandez P, Reza R, Garg N, Garg S, Garvey W, Garza J, Gatta-Cherifi B, Gelev V, Geller S, Geohas J, Georgiev B, Ghazi A, Gilbert M, Gilinskaya O, Gislason G, Yavuz D, Albarrán O, Gordeev I, Gorton S, Goudev A, Valderhaug T, Groenemeijer B, Gul I, Gullestad L, Gurieva I, Guseva G, Hagenow A, Haluzik M, Halvorsen S, Hammoudi N, Hanaoka K, Hancu N, Hanusch U, Harris K, Harris B, Hartleib M, Hartman A, Hata Y, Heimer B, Herman L, Herzog W, Hewitt E, Heymer P, Hiremath S, Hjelmesaeth J, Høgalmen R, Høivik H, Holmer H, Horoshko O, Houser P, Hove J, Hsieh I, Hulot J, Hussein Z, Ilashchuk T, Ilveskoski E, Ipatko I, Iranmanesh A, Isawa T, Issa M, Iteld B, Iwasawa T, Jabbar D, Jackson R, Jackson-Voyzey E, Jacob S, Jaffrani N, Jardula M, Jastreboff A, Jensen S, Jerkins T, Jimenez-Ramos S, Singh S, Johnson W, Joyce J, Jozefowska M, Jugnundan P, Jungmair W, Jurowiecki J, Kadokami T, Kahali D, Kahrmann G, Kaiser S, Kalmucki P, Kanadasi M, Kandath D, Kania G, Kannan J, Kapp C, Karczmarczyk A, Kartalis A, Kaser S, Kasim S, Kastelic R, Kato T, Katova T, Kaul U, Kautzky-Willer A, Kawanishi M, Kayikcioglu M, Kazakova E, Keeling P, Kempe H, Kereiakes D, Kerneis M, Keski-Opas T, Khadra S, Khaisheva L, Kharakhulakh M, Khlevchuk T, Khoo J, Kiatchoosakun S, Kinoshita N, Kinoshita M, Kitamura R, Kiyosue A, Klavina I, Klein E, Klimsa Z, Klonoff D, Klug E, Kobalava Z, Kodera S, Koga T, Kokkinos A, Koleckar P, Könyves L, Koren M, Kormann A, Kostner K, Kreutzmann K, Krishinan S, Krishnasamy S, Krivosheeva I, Kruljac I, Kubicki T, Kuchar L, Kujawiak M, Kunishige H, Kurtinecz M, Lisboa H, Kushnir M, Kyyak Y, Lace A, Lakka T, Lalic N, Lalic K, Lambadiari V, Lanaras L, Lang C, Langlois M, Lash J, Latkovskis G, Lau D, Soto J, Le Roux C, Ledesma G, Lee L, Lee T, Lee K, Lehrke M, Leite S, Leksycka A, Lenzmeier T, Leonetti F, Leonidova V, Lepor N, Leung M, Levchenko O, Levins P, Levy L, Lewis M, Liberopoulos E, Liberty I, Lindholm C, Lingvay I, Linhart A, Liu M, Liu J, Lofton H, Logemann T, Lombaard J, Lombard L, Lorraine R, Lovell C, Ludvik B, Lukaszewicz M, Lupkovics G, Lupovitch S, Lupu S, Lynch M, Lysak Z, Lysenko T, Maeda H, Maeda I, Mæng M, Mahajan A, Maher V, Maia L, Makotoko E, Malavazos A, Malecha J, Malicherova E, Manita M, Mannucci E, Mareev V, Marin L, Markova T, Marso S, Martens F, Martinez C, Cano C, Martins C, Comas L, Matsumoto T, Mcdonald K, Mcgowan B, Mcgrew F, Mclean B, Mcpherson D, Torres J, Meyers P, Meyhöfer S, Raya P, Milanova M, Milicic D, Miller G, Mills R, Mîndrescu N, Mingrone G, Minkova D, Mirani M, Miras A, Mistodie C, Mitomo S, Mittal S, Miyake T, Miyamoto N, Molony D, Monteiro P, Mooe T, Moosa N, Portillo C, Villegas E, Morawski E, Morbey C, Morin R, Morisaki K, Morosanu M, Mosenzon O, Mostovoy Y, Munir I, Muratori F, Murray R, Murthy A, Myint M, Myshanych G, Nafornita V, Nagano T, Nair S, Nakhle S, Natsuaki M, Nayak B, Nibouche D, Nicholls S, Nicolau J, Nicolescu G, Nierop P, Niskanen L, Ntaios G, Nygård O, Oaks J, Obrezan A, O'donnell P, Oguri M, Oguzhan A, Oh F, Ohsugi M, Okada Y, Okayama H, Onaca A, Onaka H, Oneil P, Ong T, Ong S, Ono Y, Opsahl P, Ostrowska L, Oviedo A, Ozdogan O, Ozpelit E, Pagkalos E, Pagotto U, Páll D, Pandey A, Parkhomenko O, Parvathareddy K, Patel M, Patsilinakos S, Paul N, Pedersen S, Pereira I, Pereira E, Terns P, Perez-Vargas E, Pergaeva Y, Perkelvald A, Peskov A, Peter J, Peters K, Petit C, Petrov I, Philis-Tsimikas A, Pietilä M, Pinto F, Piros A, Piyayotai D, Platonov D, Poirier P, Pop L, Popa B, Pop-Busui R, Poremba J, Porto A, Postadzhiyan A, Pothineni R, Potu R, Powell T, Prafulla K, Prager R, Prakova-Teneva Z, Pratley R, Price H, Pulka G, Pullman J, Punt Z, Purighalla R, Purnell P, Qureshi M, Rabasa-Lhoret R, Raikhel M, Rancane G, Randeva H, Rasouli N, Pintilei D, Reyes C, Rezgale I, Rice E, Riley T, Risser J, Ristic A, Fernández M, Robbins D, Robitaille Y, Rodbard H, Plazas J, Römer T, Rosen G, Rosman A, Rossi P, Rudenko L, Ruffin O, Ruhani A, Runev N, Ruyatkin D, Ruzic A, Ryabov V, Rydén L, Saggar S, Sakamoto T, Salter T, Samal A, Samoilova Y, Sanabria H, Sancak S, Sangrigoli R, Sansanayudh N, Santini F, Saraiva J, Sardinov R, Sargeant W, Sari R, Sathananthan A, Sathyapalan T, Sato A, Sauter J, Sbraccia P, Schaap J, Schaum T, Schiele F, Scott J, Lieberman G, Segner A, Senior R, Sergeeva-Kondrachenko M, Serota H, Serusclat P, Sethi R, Shah M, Shah N, Shalaev S, Sharma R, Sharma S, Shaydyuk O, Shea H, Shechter M, Shehadeh N, Shirazi M, Shlesinger Y, Shneker A, Shutemova E, Siasos G, Siddiqui I, Sidey J, Sigal F, Sime I, Singh N, Siraj E, Sivalingam K, Skoczylas G, Smith S, Smolenskaya O, Snyder B, Sofer Y, Sofley C, Solano R, Sonmez Y, Sorokin M, González A, Sotolongo C, Soufer J, Selcukbiricik O, Spaic T, Spriggs D, Sreenan S, Stahl H, Stamatelopoulos K, Stanislavchuk M, Stankovic G, Stasek J, Steg G, Steindorf J, Stephan D, Stewart J, Still C, St-Maurice F, Stogowska-Nikiciuk B, Stoker J, Stokic E, Strzelecka A, Sturm K, Sueyoshi A, Sugiura T, Sultan S, Suplotova L, Suwanagool A, Suwanwalaikorn S, Sveklina T, Swanson N, Swart H, Swenson B, Szyprowska E, Tait G, Takács R, Takeuchi Y, Tamirisa A, Tanaka H, Tatovic D, Tellier G, Teragawa H, Teterovska D, Thomas N, Thuan J, Tinahones F, Tisheva-Gospodinova S, Toarba C, Todoriuk L, Tokmakova M, Tonstad S, Toplak H, Tran H, Tripathy D, Trusau A, Tsabedze N, Tsougos E, Tsoukas G, Tuccinardi D, Tuna M, Turatti L, Tziomalos K, Udommongkol C, Ueda O, Ukkola O, Unubol M, Urbach D, Triana M, Usdan L, Vaidya B, Vale N, Vallieres G, Van Beek A, Van De Borne P, Van Der Walt E, Van Der Zwaan C, Van Nieuwenhuizen E, Van Zyl L, Vanduynhoven P, Varghese K, Vasileva S, Vassilev D, Vathesatogkit, Velychko V, Vercammen C, Verges B, Verma S, Verwerft J, Vesela A, Veselovskaya N, Vettor R, Veze I, Vijan V, Vijayaraghavan R, Villarino A, Vincent R, Vinogradova O, Vishlitzky V, Vlad A, Vladu I, Vo A, Von Engelhardt C, Von Münchhausen C, Vorobyeva O, Vossenberg T, Vrolix M, Vukicevic M, Vyshnyvetskyy I, Wadvalla S, Wagner J, Wakeling J, Wallace J, Mohamed W, Wander G, Ward K, Warren M, Watanabe A, Weber B, Weintraub H, Weisnagel J, Welker J, Wendisch U, Wenocur H, Wierum C, Wilding J, William M, Wilson P, Wilson J, Wong Y, Wongcharoen W, Wozniak I, Wu C, Wyatt N, Wynne A, Yamaguchi H, Yamasaki M, Yazici D, Yeh H, Yotov Y, Yuan Q, Zacher J, Zagrebelnaya O, Zaidman C, Zalevskaya A, Zarich S, Zatelli M, Zeller H, Zhdanova E, Zornitzki T, Zrazhevskiy K, Zykov M, Lincoff A, Ryan D, Colhoun H, Deanfield J, Emerson S, Kahn S, Kushner R, Plutzky J, Brown-Frandsen K, Hovingh G, Hardt-Lindberg S, Tornøe C. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet 2024, 404: 773-786. PMID: 39181597, DOI: 10.1016/s0140-6736(24)01498-3.Peer-Reviewed Original ResearchConceptsReduced ejection fractionOnce-weekly subcutaneous semaglutideHistory of heart failureEjection fractionHeart failureHeart failure subtypesAtherosclerotic cardiovascular diseaseSubcutaneous semaglutideBaseline characteristicsCardiovascular diseaseEffects of once-weekly subcutaneous semaglutideNew York Heart Association statusCardiovascular outcomesInteractive web response systemIncidence of clinical eventsGLP-1 receptor agonistsHeart failure endpointsSafety of semaglutideSubtypes of heart failureWeb response systemClinical heart failureEffect of semaglutideDouble-blind mannerSerious adverse eventsPhase 3 trialEnding Weight Stigma to Advance Health Equity
Pearl R, Donze L, Rosas L, Agurs-Collins T, Baskin M, Breland J, Byker Shanks C, Cooksey Stowers K, Johnson S, Lee B, Martin M, Mujuru P, Odoms-Young A, Panza E, Pronk N, Calicutt K, Nadglowski J, Nece P, Tedder M, Chow L, Krishnamurti H, Jay M, Xi D, Jastreboff A, Stanford F. Ending Weight Stigma to Advance Health Equity. American Journal Of Preventive Medicine 2024, 67: 785-791. PMID: 38945180, DOI: 10.1016/j.amepre.2024.06.021.Peer-Reviewed Original ResearchEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, Bozkurt B, Budoff M, Butler J, Cherney D, DeFronzo R, Del Prato S, Eckel R, Filippatos G, Fonarow G, Fonseca V, Garvey W, Giorgino F, Grant P, Green J, Greene S, Groop P, Grunberger G, Jastreboff A, Jellinger P, Khunti K, Klein S, Kosiborod M, Kushner P, Leiter L, Lepor N, Mantzoros C, Mathieu C, Mende C, Michos E, Morales J, Plutzky J, Pratley R, Ray K, Rossing P, Sattar N, Schwarz P, Standl E, Steg P, Tokgözoğlu L, Tuomilehto J, Umpierrez G, Valensi P, Weir M, Wilding J, Wright E. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism 2024, 159: 155931. PMID: 38852020, DOI: 10.1016/j.metabol.2024.155931.Peer-Reviewed Original ResearchChronic kidney diseaseAtherosclerotic cardiovascular diseaseHeart failureMetabolic diseasesCardiorenal risk factorsEssentials of managementPractice recommendationsType 2 diabetesImprove patient outcomesVolunteer task forcePrimary care physiciansMetabolic comorbiditiesMultispecialty consensusOutcome trialsManagement of personsKidney diseaseLiver diseasePathophysiological pathwaysPulmonary diseaseRisk factorsSteatotic liver diseaseManagement of diabetesCardiovascular diseasePatient outcomesCare physiciansOnce-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial
Jastreboff A, Kaplan L, Frias J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M, Blüher M. Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial. Diabetologie Und Stoffwechsel 2024, 19: s77-s78. DOI: 10.1055/s-0044-1785389.Peer-Reviewed Original ResearchRetatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study
Coskun T, Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Hartman M, Haupt A, Milicevic Z, Seufert J. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study. Diabetologie Und Stoffwechsel 2024, 19: s72-s73. DOI: 10.1055/s-0044-1785379.Peer-Reviewed Original Research
2023
Reflecting on a Year at the Helm of Diabetes Care.
Kahn S, Anderson C, Buse J, Selvin E, Angell S, Aroda V, Cheng A, Danne T, Echouffo-Tcheugui J, Fitzpatrick S, Gadgil M, Gastaldelli A, Gloyn A, Green J, Jastreboff A, Kanaya A, Kandula N, Kovesdy C, Laiteerapong N, Nadeau K, Pettus J, Pop-Busui R, Posey J, Powe C, Rebholz C, Rickels M, Sattar N, Shaw J, Sims E, Utzschneider K, Vella A, Zhang C. Reflecting on a Year at the Helm of Diabetes Care. Diabetes Care 2023, 47: 4-6. PMID: 38117988, DOI: 10.2337/dci23-0089.Peer-Reviewed Original ResearchEligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original ResearchTriple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
Jastreboff A, Kaplan L, Hartman M. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. New England Journal Of Medicine 2023, 389: 1629-1630. PMID: 37888927, DOI: 10.1056/nejmc2310645.Peer-Reviewed Original ResearchNaltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionReducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targetsTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeks